Phospho-EPHA4 (Y596) Antibody

What is EphA4 and what is the significance of Y596 phosphorylation?

EphA4 is a receptor tyrosine kinase that binds membrane-bound ephrin family ligands on adjacent cells, leading to contact-dependent bidirectional signaling. It has the unique property among Eph receptors to bind and be physiologically activated by both GPI-anchored ephrin-A and transmembrane ephrin-B ligands, including EFNA1 and EFNB3 . Tyrosine 596 (Y596) is a conserved residue in the juxtamembrane (JM) domain of EphA4 that undergoes autophosphorylation as one of the first events in receptor activation . This phosphorylation event is critical for initiating downstream signaling cascades that regulate cell morphology and integrin-dependent cell adhesion through modulation of Rac, Rap, and Rho GTPases activity . The phosphorylation of Y596 creates a binding site for the SH2 domain of signaling proteins such as Src, which then participate in propagating the signal further downstream .

How does the Phospho-EPHA4 (Y596) Antibody work in detecting EphA4 activation?

The Phospho-EPHA4 (Y596) Antibody is a rabbit polyclonal antibody specifically designed to recognize the phosphorylated form of tyrosine 596 in the EphA4 receptor . This antibody binds to the phosphorylated Y596 residue and not to the unphosphorylated form, making it a valuable tool for monitoring EphA4 activation status. In Western blot applications, the antibody detects a band of approximately 110 kDa, corresponding to the phosphorylated EphA4 receptor . The specificity of this antibody for the phosphorylated form allows researchers to quantify the degree of EphA4 activation under different experimental conditions or following various stimuli, such as ephrin ligand binding or pharmacological treatments.

What experimental applications is the Phospho-EPHA4 (Y596) Antibody suitable for?

The Phospho-EPHA4 (Y596) Antibody has been validated for Western blot (WB) applications using human samples . In Western blot, it can be used at a dilution of 1/500, as demonstrated in experiments with Jurkat cell extracts . Beyond direct antibody applications, the phospho-specific recognition of Y596 has been leveraged in the development of FRET-based biosensors for visualizing EphA4 activation dynamics in living cells . These biosensors utilize the binding interaction between the phosphorylated Y596 residue and the SH2 domain of Src to detect conformational changes induced by EphA4 activation . While the antibody itself is primarily validated for Western blot, the principles of its target recognition underpin more advanced applications in cellular imaging and real-time kinase activity monitoring.

What is the specificity of the Phospho-EPHA4 (Y596) Antibody?

The Phospho-EPHA4 (Y596) Antibody demonstrates high specificity for the phosphorylated Y596 residue of EphA4. This specificity has been validated through control experiments using antigen-specific peptide blocking, where the antibody signal is abolished when pre-incubated with the phosphorylated peptide corresponding to the Y596 region . The importance of this specificity is further supported by studies with FRET biosensors based on the same recognition principle, where mutations of the Y596 residue to phenylalanine (Y596F) completely eliminated the FRET response upon EphA4 activation . This demonstrates that the antibody's recognition is dependent on both the specific amino acid sequence surrounding Y596 and its phosphorylation status, making it a reliable tool for specifically detecting activated EphA4 receptor.

How does EphA4 signaling differ from other receptor tyrosine kinases?

EphA4 signaling is distinct from other receptor tyrosine kinases in several key aspects. First, EphA4 exhibits remarkable promiscuity in ligand binding, with the unique ability among Eph receptors to bind and be physiologically activated by both ephrin-A and ephrin-B family ligands . Second, EphA4 mediates bidirectional signaling, where the signaling pathway downstream of the receptor is termed forward signaling, while the signaling pathway downstream of the ephrin ligand is termed reverse signaling . This bidirectional communication enables complex cell-cell interactions during development and in adult tissues. Third, EphA4 plays specialized roles in nervous system development, controlling different steps of axonal guidance including the establishment of corticospinal projections and the segregation of motor and sensory axons . In addition to these functions, EphA4 contributes to synaptic plasticity, repair after injury, angiogenesis, and various cell-cell signaling processes throughout development .

What are the methodological considerations when using Phospho-EPHA4 (Y596) Antibody in FRET-based biosensors?

When designing FRET-based biosensors incorporating the principles of Phospho-EPHA4 (Y596) recognition, several methodological considerations must be addressed. First, the selection of appropriate FRET pairs is critical; enhanced CFP (ECFP) and YPet have been successfully employed to maximize sensitivity of EphA4 biosensors . The structural design must include: (1) the SH2 domain of c-Src that specifically binds to phosphorylated Y596, (2) a flexible linker peptide, and (3) the substrate sequence containing the Y596 residue, all positioned between the fluorescent protein pairs .

For validation, researchers should include essential controls: (1) mutation of Y596 to phenylalanine (Y596F) in the substrate peptide and (2) mutation of Arg175 to valine (R175V) in the binding site of the SH2 domain—both mutations should eliminate FRET response upon EphA4 activation . Reversibility of the biosensor should be confirmed using phosphatases (e.g., lambda protein phosphatase) to demonstrate that signals depend on substrate phosphorylation . Additionally, specificity testing against other kinases (e.g., PDGF receptor, Src kinase) is essential to ensure the biosensor primarily responds to EphA4 activity .

How does membrane microdomain localization affect EphA4 activation and signaling?

Membrane microdomain localization significantly impacts EphA4 activation and signaling dynamics, as revealed by studies using targeted FRET biosensors. EphA4 biosensors have been directed to different membrane compartments through lipid modifications: acylation (using the Lyn-targeting motif) targets the biosensor to raft-like microdomains, while prenylation (using the KRas-targeting motif) directs it to non-raft regions .

While both raft and non-raft targeted biosensors showed similar responses to pervanadate (PVD) stimulation, they exhibited strikingly different behaviors upon ephrin ligand stimulation . The KRas-EphA4 biosensor in non-raft regions displayed a rapid and robust response (20-25% increase in FRET ratio) to ephrinA3, whereas the Lyn-EphA4 biosensor in raft-like domains showed only minimal activation even after 10 minutes of stimulation . Similar differential responses were observed with ephrinA1 stimulation .

These findings indicate that active EphA4 signaling occurs predominantly in non-raft membrane regions upon initial ligand binding, suggesting that membrane microdomain composition plays a crucial role in regulating EphA4 activation kinetics and potentially influencing downstream signaling pathway selection.

What is the role of cytoskeleton in regulating EphA4 phosphorylation at Y596?

The cytoskeleton plays a significant regulatory role in EphA4 Y596 phosphorylation and subsequent signaling. Experiments using cytochalasin D (cytoD), which disrupts actin filaments, revealed dramatic alterations in EphA4 activation patterns across different membrane microdomains . In cells with disrupted cytoskeleton, EphA4 activation in raft-like microdomains was substantially enhanced compared to untreated cells .

Specifically, while KRas-EphA4 biosensors in non-raft regions maintained similar activation levels (20-25% FRET ratio increase) after cytochalasin D treatment, Lyn-EphA4 biosensors in raft-like domains showed dramatically increased responses (35-40% change in FRET ratio) . This effect persisted even at lower cytochalasin D concentrations that caused clear disruption of actin cytoskeleton without dramatic cell morphology changes .

These findings suggest that the intact actin cytoskeleton normally constrains EphA4 activation in raft-like microdomains, possibly by restricting receptor mobility or clustering. Cytoskeletal elements may therefore act as gatekeepers controlling compartmentalized EphA4 signaling, ensuring appropriate spatial regulation of receptor activation and downstream effects on cellular morphology and behavior.

How can researchers distinguish between forward and reverse signaling when studying EphA4 activation?

To distinguish between these signaling modes, researchers should implement a multi-faceted approach:

• Use soluble ephrin ligands fused to Fc fragments (ephrin-Fc) to specifically activate forward signaling without engaging reverse signaling

• Pre-cluster ephrin-Fc complexes with anti-Fc antibodies to enhance receptor clustering and activation

• Employ EphA4-Fc fusion proteins as control reagents that can trigger reverse signaling without activating EphA4 receptors

• Monitor Y596 phosphorylation as a definitive marker of forward signaling using the phospho-specific antibody

• Track downstream effectors specific to forward signaling pathways, such as Rac, Rap, and Rho GTPases activation

Additionally, cell type-specific approaches can be valuable—using cells that express EphA4 but not ephrin ligands allows isolated study of forward signaling, while analyzing effects in ephrin-expressing cells lacking EphA4 enables focused examination of reverse signaling components.

What are the limitations of using Phospho-EPHA4 (Y596) Antibody in studying EphA4 dynamics?

While the Phospho-EPHA4 (Y596) Antibody provides valuable insights into EphA4 activation, researchers should be aware of several limitations. First, the antibody only captures a single phosphorylation event within a complex activation cascade. EphA4 function depends on multiple phosphorylation sites beyond Y596, and their sequential or combinatorial effects cannot be assessed with this antibody alone .

Second, Western blot applications provide only static snapshots of phosphorylation status in cell populations, lacking spatial and temporal resolution needed to understand dynamic signaling events in individual cells. While FRET biosensors based on Y596 phosphorylation recognition can overcome this limitation, they introduce different constraints such as potential interference with endogenous signaling components .

Third, the antibody has been primarily validated with human samples in Western blot applications, potentially limiting cross-species applicability without further validation . Additionally, complexities in signaling arising from EphA4's promiscuous binding to multiple ephrin ligands and potential heteromeric receptor formation cannot be fully addressed through Y596 phosphorylation monitoring alone.

Finally, understanding how Y596 phosphorylation relates to specific functional outcomes requires complementary approaches, as the same phosphorylation event may lead to different cellular responses depending on contextual factors such as cell type, developmental stage, and concurrent signaling pathways.

How do different ephrin ligands affect the phosphorylation of Y596 in EphA4?

Different ephrin ligands induce varying degrees of Y596 phosphorylation in EphA4, reflecting the receptor's unique promiscuity in ligand binding. EphA4 can be physiologically activated by both GPI-anchored ephrin-A and transmembrane ephrin-B ligands, including EFNA1 and EFNB3 . When measured using FRET biosensors specific for Y596 phosphorylation, ephrinA1 and ephrinA3 (high-affinity ligands) produced robust responses with approximately 20% FRET ratio changes, while ephrinB2 (a lower-affinity ligand) yielded significantly smaller responses at equivalent concentrations .

This ligand-dependent activation pattern correlates with the reported binding affinities of different ephrins for EphA4. The differential phosphorylation induced by various ligands likely contributes to the diverse functional outcomes of EphA4 signaling in different cellular contexts. For instance, in axonal guidance, different ephrin gradients may induce varying levels of Y596 phosphorylation, translating into distinct cytoskeletal rearrangements and directional responses.

Additionally, the kinetics of Y596 phosphorylation may vary between ligands, with implications for signal duration and downstream pathway activation. Researchers should carefully select appropriate ephrin ligands based on their experimental goals and the specific biological context under investigation, recognizing that ligand choice will impact both the magnitude and potentially the functional consequences of Y596 phosphorylation.

What controls should be included when using Phospho-EPHA4 (Y596) Antibody in Western blot experiments?

When conducting Western blot experiments with the Phospho-EPHA4 (Y596) Antibody, researchers should include several critical controls to ensure reliable and interpretable results:

• Antigen competition control: Pre-incubate the antibody with the phosphorylated peptide antigen to demonstrate binding specificity, as seen in the Abcam validation where signal was abolished in Jurkat cell extract treated with antigen-specific peptide

• Phosphatase treatment control: Process duplicate samples with lambda phosphatase to dephosphorylate Y596, which should eliminate antibody binding and confirm phosphorylation-dependent recognition

• Y596F mutant control: Where possible, include samples expressing EphA4 with Y596F mutation as a negative control, as this mutation eliminates the phosphorylation site

• Total EphA4 antibody blotting: Probe parallel samples with an antibody recognizing total EphA4 (regardless of phosphorylation status) to normalize phospho-signal to total protein expression

• Stimulation controls: Include both unstimulated samples and positive controls stimulated with known activators (e.g., ephrinA1, ephrinA3, or pervanadate)

• Inhibitor controls: Where relevant, include samples treated with EphA4 inhibitors like peptide antagonist APY-d3 to confirm signal specificity

• Cell line controls: Include both EphA4-expressing and EphA4-null cell lines to verify antibody specificity, similar to experiments comparing EphA4-expressing 293AD cells with parental cells

These controls collectively ensure that the detected signal truly represents phosphorylated Y596 in EphA4 rather than non-specific binding or technical artifacts.

How can researchers quantify the level of EphA4 Y596 phosphorylation in different experimental conditions?

Researchers can employ several complementary approaches to quantify EphA4 Y596 phosphorylation levels with precision:

Western Blot Densitometry:

• Run parallel blots for phospho-Y596 and total EphA4

• Quantify band intensities using software like ImageJ or commercial alternatives

• Calculate the ratio of phospho-Y596 to total EphA4 signal to normalize for expression differences

• Include a standard curve with known quantities of recombinant phosphorylated protein for absolute quantification

FRET-Based Biosensors:

• Express the EphA4 FRET biosensor in cells of interest

• Measure ECFP/FRET emission ratios before and after stimulation

• Calculate the percentage change in ratio to quantify relative activation levels

• For comparing different conditions, normalize to maximum response obtained with pervanadate (PVD) treatment, which typically yields ~100% FRET change

Phospho-Specific ELISA:

• Develop sandwich ELISA using capture antibody against total EphA4 and detection with the Phospho-EPHA4 (Y596) Antibody

• Generate standard curves using recombinant phosphorylated EphA4

• Calculate absolute quantities of phospho-Y596 EphA4 in experimental samples

Intracellular Flow Cytometry:

• Fix and permeabilize cells from different experimental conditions

• Stain with fluorophore-conjugated Phospho-EPHA4 (Y596) Antibody

• Analyze by flow cytometry to determine phosphorylation levels across cell populations

• Calculate mean fluorescence intensity (MFI) as a measure of phosphorylation